Eris Lifesciences Ltd
NSE:ERIS

Watchlist Manager
Eris Lifesciences Ltd Logo
Eris Lifesciences Ltd
NSE:ERIS
Watchlist
Price: 1 465.5 INR -0.1% Market Closed
Market Cap: 199.5B INR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ERIS stock under the Base Case scenario is 1 637.44 INR. Compared to the current market price of 1 465.5 INR, Eris Lifesciences Ltd is Undervalued by 11%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ERIS Relative Value
Base Case
1 637.44 INR
Undervaluation 11%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

7.3
P/S
P/S
Price to Sales
7.3
vs History
15
vs Industry
20
Median 3Y
6.5
Median 5Y
6.6
Industry
2.4
Forward
6.6
More Details
60.5
P/E
P/E
Price to Earnings
60.5
vs History
0
vs Industry
7
Median 3Y
30.5
Median 5Y
25
Industry
20.3
Forward
53.1
More Details
27.2
P/OCF
P/OCF
Price to OCF
27.2
vs History
30
vs Industry
17
Median 3Y
26.7
Median 5Y
25.8
Industry
15.6
More Details
10
P/FCFE
P/FCFE
Price to FCFE
10
vs History
58
vs Industry
30
Median 3Y
31.7
Median 5Y
18.7
Industry
23.1
More Details
7.2
P/B
P/B
Price to Book Value
7.2
vs History
0
vs Industry
10
Median 3Y
4.9
Median 5Y
5.1
Industry
2
More Details
7.9
EV/S
EV/S
Enterprise Value to Sales
7.9
vs History
7
vs Industry
18
Median 3Y
6.7
Median 5Y
6.6
Industry
2.5
Forward
7.2
More Details
10.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
10.5
vs History
3
vs Industry
22
Median 3Y
8.4
Median 5Y
8.3
Industry
4.8
More Details
24.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
24.8
vs History
3
vs Industry
16
Median 3Y
20.1
Median 5Y
19.7
Industry
12.5
Forward
20.6
More Details
35
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
35
vs History
3
vs Industry
13
Median 3Y
26
Median 5Y
23.4
Industry
15.7
Forward
29.7
More Details
29.6
EV/OCF
EV/OCF
Enterprise Value to OCF
29.6
vs History
20
vs Industry
16
Median 3Y
28.2
Median 5Y
27
Industry
14.1
More Details
35.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
35.1
vs History
38
vs Industry
15
Median 3Y
33.4
Median 5Y
33.4
Industry
17.6
More Details
3.3
EV/IC
EV/IC
Enterprise Value to IC
3.3
vs History
63
vs Industry
24
Median 3Y
3.3
Median 5Y
3.7
Industry
1.8
More Details

Multiples Across Competitors

ERIS Competitors Multiples
Eris Lifesciences Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Eris Lifesciences Ltd
NSE:ERIS
199.3B INR 7.3 60.5 24.8 35
US
Eli Lilly and Co
NYSE:LLY
704.4B USD 14.4 63.3 34.1 37.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
375.6B USD 4.2 17.2 12.6 16.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.5 18.8 12.4 14.1
CH
Roche Holding AG
SIX:ROG
207.4B CHF 3.4 25.1 9.4 11
CH
Novartis AG
SIX:NOVN
178.8B CHF 4.1 16.9 10 13.4
UK
AstraZeneca PLC
LSE:AZN
157.6B GBP 3.8 27 130.3 196.5
US
Merck & Co Inc
NYSE:MRK
196.8B USD 3.1 11.3 8.1 9.8
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
130.2B USD 2.1 16.5 7.2 10.1
P/E Multiple
Earnings Growth PEG
IN
Eris Lifesciences Ltd
NSE:ERIS
Average P/E: 28.5
60.5
24%
2.5
US
Eli Lilly and Co
NYSE:LLY
63.3
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.2
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
18.8
18%
1
CH
Roche Holding AG
SIX:ROG
25.1
32%
0.8
CH
Novartis AG
SIX:NOVN
16.9
17%
1
UK
AstraZeneca PLC
LSE:AZN
27
36%
0.7
US
Merck & Co Inc
NYSE:MRK
11.3
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.5
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Eris Lifesciences Ltd
NSE:ERIS
Average EV/EBITDA: 396
24.8
29%
0.9
US
Eli Lilly and Co
NYSE:LLY
34.1
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.6
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
12.4
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.4
6%
1.6
CH
Novartis AG
SIX:NOVN
10
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.3
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.1
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.2
2%
3.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Eris Lifesciences Ltd
NSE:ERIS
Average EV/EBIT: 1 700.1
35
30%
1.2
US
Eli Lilly and Co
NYSE:LLY
37.3
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.5
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.1
14%
1
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
13.4
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
196.5
21%
9.4
US
Merck & Co Inc
NYSE:MRK
9.8
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
10%
1

See Also

Summary
ERIS intrinsic value, competitors valuation, and company profile.
DCF Valuation
ERIS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ERIS stock valuation using valuation multiples.
Wall Street Estimates
ERIS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ERIS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.